Browsing by Author "El-Feky G.S."

Now showing 1 - 6 of 6

Alginate coated chitosan nanogel for the controlled topical delivery of Silver sulfadiazine
(Elsevier Ltd, 2017) El-Feky G.S.; El-Banna S.T.; El-Bahy G.S.; Abdelrazek E.M.; Kamal M.; Pharmaceutical Technology Department; National Research Center; DokkiCairo; Egypt; Faculty of Pharmacy; October University for Modern Sciences and Arts; Egypt; Spectroscopy Department; Physics Division; National Research Centre; Dokki; Giza; Egypt; Physics Department; Faculty of Science; Mansoura University; Mansoura; Egypt; Physics Department; Faculty of Science; Taibah University; Al-Ula; Saudi Arabia
Burn wounds environment favors the growth of micro-organisms causing delay in wound healing. The traditional treatment with antimicrobial creams offer inaccurate doses. The aim of the present study is to formulate and evaluate different silver sulfadiazine loaded nanogel formulations. A factorial design experiment was used for the identification of critical process parameters and for the optimization of the respective process conditions. The prepared drug loaded nanogels were characterized for their particle size, zeta potential, entrapment efficiency and swelling index in order to demonstrate their physicochemical properties, in addition, FTIR, TEM, SEM and in vitro release were used for characterization. The release profile of all tested nanogels showed an initial burst followed by a slow and continuous release rate. An optimum nanogel formulation was predicted by the JMP� software according to the stated prediction expressions and was composed of 0.4% sodium alginate (ALG) and 0.414% Silver sulfadiazine (SSD). The optimized formulation showed higher therapeutic efficacy in vivo when compared to market product. � 2017 Elsevier Ltd
Flexible nano-sized lipid vesicles for the transdermal delivery of colchicine; in vitro/in vivo investigation
(Editions de Sante, 2019) El-Feky G.S.; El-Naa M.M.; Mahmoud A.A.; Department of Pharmaceutical Technology; Pharmaceutical and Drug Industries Research Division; National Research Center; Dokki; Cairo; Egypt; October University for Modern Sciences and Arts; Egypt; Department of Pharmacology and Toxicology; Faculty of Pharmacy; Fayoum University; Egypt; Department of Pharmaceutics and Pharmaceutical Technology; Faculty of Pharmaceutical Sciences and Pharmaceutical Industries; Future University; Cairo; Egypt
Colchicine (CL) is the most effective treatment of acute gout, however, it is associated with side effects in 80% of the patients at therapeutic doses, in addition, it's a water-soluble strong base (pKa ?12.8) which ionizes at physiological gastrointestinal pH resulting in low oral bioavailability of 44%. This work employed enhancing the bioavailability and reducing the side effects of CL through combining the benefits of the transdermal route together with those of elastic lipid nano-vesicles. Transfersomes (TRs) have been studied as vehicles for transdermal drug delivery, however, poor encapsulation of drugs and drug leaking of the vesicles required complexation of CL with ?-cyclodextrin (?-CD) before formulation. The composition of the designed CL-?-CD-TR was studied to balance the flexibility of the vesicles to their entrapment ability. CL-?-CD-TR were characterized for their shape, size, entrapment efficiency, elasticity, release profile, ex vivo skin permeation, pharmacological efficacy, and histopathological effect. Encapsulation efficiency of CL-?-CD complex in the vesicular formulations ranged from 42.3% to 93.8%. Particle size ranged from 70.6 nm to 138.5 nm and zeta potential ranged from 16.1 mV to 23.4 mV. The in vitro release of CL from the selected CL-?-CD-TR formulation (F3) showed a controlled, biphasic profile. Ex vivo study reported the great potential of F3 (CL-?-CD-TR) for skin permeation. In vivo experiment demonstrated that F3 (CL-?-CD-TR) possessed high biological efficacy with reduced skin irritation. � 2018 Elsevier B.V.
Mucosal co-delivery of ketorolac and lidocaine using polymeric wafers for dental application
(Taylor and Francis Ltd, 2018) El-Feky G.S.; Abdulmaguid R.F.; Zayed G.M.; Kamel R.; Department of Pharmaceutical Technology; National Research Center; Cairo; Egypt; Department of Pharmaceutics; Faculty of Pharmacy; October University for Modern Sciences and Arts; Cairo; Egypt; Department of Oral Medicine and Periodontology; Department Faculty of Dentistry; October University for Modern Sciences and Arts; Cairo; Egypt; Department of Pharmaceutics and Industrial Pharmacy; Faculty of Pharmacy; Al-Azhar University at Assiut; Assiut; Egypt
The current study aimed to investigate the effectiveness of a developed sodium alginate and polyvinyl-pyrrolidone K-25 (PVP K-25) polymeric wafer for the co-delivery of ketorolac and lidocaine to soft tissues for healing and pain control following gingivectomy. Nine ketorolac/lidocaine lyophilized wafers were formulated and assessed for their hydration capacity, mucoadhesion ability and in vitro release profile to select the optimum system for further clinical investigation. Wafer F6 containing 2:1 sodium alginate to PVP K-25 and 10% glycerol showed optimum properties and was selected for the clinical study. Twenty patients were included in the study and the ketorolac/lidocaine wafer was assessed versus a market product. Visual pain analog was evaluated daily for the first week and wound healing index was evaluated for one week, two weeks and one month following the procedure. The developed ketorolac/lidocaine polymeric wafer proved to be an effective method of reducing pain and discomfort together with enhancing wound healing following gingivectomy. � 2017 The Author(s).
Praziquantel in a clay nanoformulation shows more bioavailability and higher efficacy against murine Schistosoma mansoni infection
(American Society for Microbiology, 2015) El-Feky G.S.; Mohamed W.S.; Nasr H.E.; El-Lakkany N.M.; Seifel-Din S.H.; Botros S.S.; Department of Pharmaceutics; Faculty of Pharmacy; October University for Modern Sciences and Arts; Cairo; Egypt; Department of Pharmaceutical Technology; National Research Center; Cairo; Egypt; Department of Polymers and Pigments; National Research Center; Cairo; Egypt; Department of Pharmacology; Theodor Bilharz Research Institute; Giza; Egypt
Consideration of existing compounds always simplifies and shortens the long and difficult process of discovering new drugs specifically for diseases of developing countries, an approach that may add to the significant potential cost savings. This study focused on improving the biological characteristics of the already-existing antischistosomal praziquantel (PZQ) by incorporating it into montmorillonite (MMT) clay as a delivery carrier to overcome its known bioavailability drawbacks. The oral bioavailability of a PZQ-MMT clay nanoformulation and its in vivo efficacy against Schistosoma mansoni were investigated. The PZQ-MMT clay nanoformulation provided a preparation with a controlled release rate, a decrease in crystallinity, and an appreciable reduction in particle size. Uninfected and infected mice treated with PZQ-MMT clay showed 3.61- and 1.96-fold and 2.16- and 1.94-fold increases, respectively, in area under the concentration-time curve from 0 to 8 h (AUC0-8) and maximum concentration of drug in serum (Cmax), with a decrease in elimination rate constant (kel) by 2.84- and 1.35-fold and increases in the absorption rate constant (ka) and half-life (t1/2e) by 2.11- and 1.51-fold and 2.86- and 1.34-fold, respectively, versus the corresponding conventional PZQ-treated groups. This improved bioavailability has been expressed in higher efficacy of the drug, where the dose necessary to kill 50% of the worms was reduced by >3-fold (PZQ 50% effective dose [ED50] was 20.25 mg/kg of body weight for PZQ-MMT clay compared to 74.07 mg/kg for conventional PZQ), with significant reduction in total tissue egg load and increase in total immature, mature, and dead eggs in most of the drug-treated groups. This formulation showed better bioavailability, enhanced antischistosomal efficacy, and a safer profile despite the longer period of residence in the systemic circulation. Although the conventional drug's toxicity was not examined, animal mortality rates were not different between groups receiving the test PZQ-clay nanoformulation and conventional PZQ. Copyright 2015, American Society for Microbiology. All Rights Reserved.
Synthesis, characterization, release kinetics and toxicity profile of drug-loaded starch nanoparticles
(Elsevier B.V., 2015) El-Naggar M.E.; El-Rafie M.H.; El-sheikh M.A.; El-Feky G.S.; Hebeish A.; Textile Research Division; National Research Centre (Affiliation ID: 60014618); 33 Behouth St.; Dokki; Giza; Egypt; Pharmaceutical Technology Department Centre (Affiliation ID: 60014618); National Research Centre; Egypt; Pharmaceutics Department; Faculty of Pharmacy; October University for Modern Sciences and Arts; Egypt
The current research work focuses on the medical application of the cost-effective cross-linked starch nanoparticles, for the transdermal delivery using Diclofenac sodium (DS) as a model drug. The prepared DS-cross-linked starch nanoparticles were synthesized using nanoprecipitation technique at different concentrations of sodium tripolyphosphate (STPP) in the presence of Tween 80 as a surfactant. The resultant cross-linked starch nanoparticles loaded with DS were characterized using world-class facilities such as TEM, DLS, FT-IR, XRD, and DSc. The efficiency of DS loading was also evaluated via entrapment efficiency as well as in vitro release and histopathological study on rat skin. The optimum nanoparticles formulation selected by the JMP� software was the formula that composed of 5% maize starch, 57.7mg DS and 0.5% STPP and 0.4% Tween 80, with particle diameter of about 21.04nm, polydispersity index of 0.2 and zeta potential of -35.3mV. It is also worth noting that this selected formula shows an average entrapment efficiency of 95.01 and sustained DS release up to 6h. The histophathological studies using the best formula on rat skin advocate the use of designed transdermal DS loaded cross-linked starch nanoparticles as it is safe and non-irritant to rat skin.The overall results indicate that, the starch nanoparticles could be considered as a good carrier for DS drug regarding the enhancement in its controlled release and successful permeation, thus, offering a promising nanoparticulate system for the transdermal delivery non-steroidal anti-inflammatory drug (NSAID). � 2015 Elsevier B.V.
Using chitosan nanoparticles as drug carriers for the development of a silver sulfadiazine wound dressing
(Elsevier Ltd, 2017) El-Feky G.S.; Sharaf S.S.; El Shafei A.; Hegazy A.A.; Pharmaceutical Technology Department; National Research Center; Dokki; Cairo; Egypt; Faculty of Pharmacy; October University for Modern Sciences and Arts; Egypt; Textile Research Division; National Research Center; Dokki; Cairo; Egypt
Burn wounds environment favors the growth of micro-organisms causing delay in wound healing. The traditional treatment with antimicrobial creams offer inaccurate doses. In the present study, a dressing coated with silver sulfadiazine (SSD) loaded chitosan nanoparticles (CSNPs) for the controlled-release of SSD into burn wound to control bacterial growth was investigated. CSNPs were formulated with different concentrations of chitosan and CM-?-CD and loaded with SSD complexed in 1:1 molar ratio with CM-?-CD, CSNPs were assessed for their particle size, polydispersity index, morphology and association efficiency. The formula showing the best characteristics was selected for the preparation of SSD loaded CSNPs wound dressing through a padding process with/without the use of cross-linker. The dressing was characterized for its physical properties, in addition, FTIR, X-ray, SEM and in vitro release were used for characterization. The dressing was proven effective for the inhibition of the growth of Gram positive and Gram negative bacteria as well as candida on an infected wound. 2016 Elsevier Ltd